摘要
目的:探究名老中医李宜瑞教授治疗小儿反复呼吸道感染(RRTIs)临床验方——复感宁的药理作用机制。方法:利用生物信息学方法筛选出复感宁中含有的中药活性成分,预测其作用靶点。通过基因表达矩阵和临床信息筛选出RRTIs特异的基因靶点,将中药靶点与RRTIs靶点进行交集,获得方剂潜在的治疗靶点。随后,导入治疗靶点至STRING数据库,获取蛋白相互作用关系,利用Cytoscape筛选出Hub靶点。统计活性化合物与Hub靶点相互作用的频数,筛选出与核心靶点相互作用最多的化合物作为核心化合物。最后,进行GO和KEGG富集分析并进行可视化。结果:本研究筛选出复感宁方剂的有效活性成分共139个,作用靶点共565个。通过生物信息学方法筛选出RRTIs差异基因共999个,其中上调差异基因165个,下调差异基因834个。共获得27个治疗靶点,其中5个Hub靶点作为关键治疗靶点,它们分别是NFKBIA、JUN、TLR4、IKBKB和CXCL8。筛选出与Hub靶点相互作用最多的10个核心化合物。富集分析得到215条通路,多与炎症、免疫相关,如T细胞受体信号通路、NF-κB信号通路和B细胞受体信号通路等。结论:复感宁通过槲皮素、鹅肌肽和3,4-O-异亚丙基莽草酸等活性成分,可作用于以NFKBIA、JUN、TLR4、IKBKB和CXCL8为核心的多个靶点,从而调节患者的免疫功能、抑制过度炎症反应,防治小儿RRTIs。
Objective:To explore the pharmacological mechanism of Fuganning,a clinical trial recipe of Professor LI Yirui,a famous veteran doctor of traditional Chinese medicine,in the treatment of recurrent respiratory tract infections(RRTIs)in children.Methods:Using bioinformatics methods to screen the active ingredients of Chinese medicine contained in Fuganning and predict its target points of action.Screening specific gene targets for RRTIs through gene expression matrix and clinical information,intersecting Chinese medicine targets with RRTIs targets,and obtaining potential therapeutic targets for the recipe.Subsequently,therapeutic targets were imported into the STRING database to obtain protein interaction relationships,and Hub targets were screened using Cytoscape.Calculate the frequency of interactions between active compounds and Hub targets,and select the compound with the most interactions with the core target as the core compound.Finally,conduct GO and KEGG enrichment analysis and visualization.Results:This study screened a total of 139 effective active ingredients and 565 target points of Fuganning Recipe.A total of 999 differentially expressed genes in RRTIs were screened using bioinformatics methods,including 165 up-regulated differentially expressed genes and 834 down-regulated differentially expressed genes.A total of 27 therapeutic targets were obtained,of which 5 Hub targets were identified as key therapeutic targets,namely NFKBIA,JUN,TLR4,IKBKB,and CXCL8.Screen out the 10 core compounds with the most interactions with Hub targets.Enrichment analysis revealed 215 pathways,mostly related to inflammation and immunity,such as T cell receptor signaling pathways and NF-κB signaling pathway and B cell receptor signaling pathway.Conclusion:Fuganning can act on multiple targets with NFKBIA,JUN,TLR4,IKBKB,and CXCL8 as the core through active ingredients such as Quercetin,Anserine,and 3,4-O-isopropylidene shikimic acid,thereby regulating patient immune function,suppressing excessive inflammatory response,and preventing and treating pediatric RRTIs.
作者
唐淑娴
钟楠
郑继源
陈晓刚
TANG Shuxian;ZHONG Nan;ZHENG Jiyuan;CHEN Xiaogang(Department of Pediatrics,Baiyun Hospital of The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou Guangdong 510470,China;The First Clinical Medical School of Guangzhou University of Chinese Medicine,Guangzhou Guangdong 510405,China;Department of Pediatrics,The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou Guangdong 510405,China)
出处
《新中医》
CAS
2023年第13期34-41,共8页
New Chinese Medicine
基金
全国名老中医专家李宜瑞传承工作室建设项目(国中医药人教函[2018]134号)
广东省名老中医专家李宜瑞传承工作室建设项目(粤中医办函[2017]209号)
关键词
小儿反复呼吸道感染
复感宁
网络药理学
炎症
Recurrent respiratory tract infections in children
Fuganning
Network pharmacology
Inflammation
作者简介
唐淑娴(1993-),女,医师,E-mail:331253527@qq.com;通信作者:陈晓刚(1973-),男,主任医师,E-mail:chenxiaogang1539@gzucm.edu.cn
